New(er) to the crew: Remimazolam, Sugammadex, & Novel Opioids

Today we’re diving into the future of anesthesia pharmacology with three major topics changing perioperative practice: Remimazolam, Sugammadex, and Novel Opioids. These medications were designed to improve what we care about most—faster recovery, safer profiles, more predictable pharmacokinetics, and better patient outcomes. In this episode, we break down: ✔️ Remimazolam – the ultra-short acting benzodiazepine with esterase metabolism, rapid recovery, and potential hemodynamic advantages over propofol ✔️ Sugammadex – the game-changing reversal agent for rocuronium and vecuronium, including dosing, mechanisms, risks, and board pearls ✔️ Novel Opioids – including biased agonists like oliceridine, and the ongoing search for analgesia with fewer side effects We also cover: 🎯 High-yield NBCRNA/NCE pharmacology points 🎯 Clinical pros and cons of each drug 🎯 Real-world barriers like cost, adoption, and safety concerns 🎯 How to think like an anesthesia provider—not just memorize drugs Whether you’re an SRNA, CRNA, resident, or anesthesia nerd who loves pharmacology, this episode will help you connect the science to clinical practice.